The effect of co-supplementation with alpha-linolenic acid and L-carnitine in migraine

Investigating the effect of co-supplementation with alpha-linolenic acid and L-carnitine on inflammatory status, oxidative stress, clinical symptoms, mental health and quality of life in women with migraine

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121216011763N57

Enrollment

Registered

2023-03-29

Start date

2023-05-06

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. G43.0

Interventions

Intervention 1: Intervention group: An alphal-inolenic acid supplement (daily 1000 mg flaxseed oil, one capsule containing 350 mg alphalinolenic acid) and L-carnitine supplement (500 mg L-carnitine).

Eligibility

Sex/Gender

Female

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients who are willing to participate in the study Migraine diagnosis by a neurologist based on the International Classification of Headache Disorders-3 (ICHD-3) Age 20 to 50 years At least one year has passed since the migraine diagnosis

Exclusion criteria

Exclusion criteria: Migraine with aura Suffering from cardiovascular diseases, hypertension, diabetes, liver and kidney diseases, malignancies and other neurological disorders Pregnancy and lactation Taking nutritional supplements (including riboflavin, feverfew, magnesium and coenzyme Q10 in the last 3 months) Taking anticoagulants Following a special diet Smoking

Design outcomes

Primary

Measure	Time frame
Clinical symptoms of migraine (severity, frequency, duration of migraine attacks). Timepoint: At baseline and after 12 weeks. Method of measurement: Visual Analogue Scale (VAS) questionnaire and clinical examination.;Serum levels of C-reactive protein (CRP). Timepoint: At baseline and after 12 weeks. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kits.;Serum level of superoxide dismutase (SOD). Timepoint: At baseline and after 12 weeks. Method of measurement: biochemical kit of KiaZist Co.;Serum level of malondialdehyde (MDA). Timepoint: At baseline and after 12 weeks. Method of measurement: biochemical kit of KiaZist Co.;Total antioxidant capacity. Timepoint: At baseline and after 12 weeks. Method of measurement: biochemical kit of KiaZist Co.;Serum level of Nitric Oxide. Timepoint: At baseline and after 12 weeks. Method of measurement: biochemical kit of KiaZist Co.;Mental health (Stress, anxiety, depression). Timepoint: At baseline and after 12 weeks. Method of measurement: Depression? Anxiety and Stress Scale-21 questionnaire (DASS-21).;Quality of Life of Migraine Patients. Timepoint: At baseline and after 12 weeks. Method of measurement: Migraine –Specific Quality of Life (MSQ) questionnaire.	—

Measure

Time frame

Clinical symptoms of migraine (severity, frequency, duration of migraine attacks). Timepoint: At baseline and after 12 weeks. Method of measurement: Visual Analogue Scale (VAS) questionnaire and clinical examination.;Serum levels of C-reactive protein (CRP). Timepoint: At baseline and after 12 weeks. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kits.;Serum level of superoxide dismutase (SOD). Timepoint: At baseline and after 12 weeks. Method of measurement: biochemical kit of KiaZist Co.;Serum level of malondialdehyde (MDA). Timepoint: At baseline and after 12 weeks. Method of measurement: biochemical kit of KiaZist Co.;Total antioxidant capacity. Timepoint: At baseline and after 12 weeks. Method of measurement: biochemical kit of KiaZist Co.;Serum level of Nitric Oxide. Timepoint: At baseline and after 12 weeks. Method of measurement: biochemical kit of KiaZist Co.;Mental health (Stress, anxiety, depression). Timepoint: At baseline and after 12 weeks. Method of measurement: Depression? Anxiety and Stress Scale-21 questionnaire (DASS-21).;Quality of Life of Migraine Patients. Timepoint: At baseline and after 12 weeks. Method of measurement: Migraine –Specific Quality of Life (MSQ) questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Gholamreza Askari

Esfahan University of Medical Sciences

askari@mui.ac.ir009837923060

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 6, 2026